科伦药业 (002422.SZ) Latest Company News

Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:
- finance.sina.cn
Aug 26, 2026, 10:44 UTC
Kelun Pharmaceutical announced a cash dividend of 1.26 yuan (pre-tax) per 10 shares.
Source:
- finance.sina.cn
Aug 26, 2026, 10:44 UTC
Kelun Pharmaceutical released its 2026 interim report, reporting revenue of 8.839 billion yuan (down 2.7% year-on-year) and net profit attributable to shareholders of 1.128 billion yuan (up 12.71% year-on-year).
Source:
- finance.sina.cn
Aug 5, 2026, 09:44 UTC
Kelun Pharmaceutical's controlling shareholder Liu Gexin released a pledge of 9.167 million shares and pledged 6.9 million shares for personal funding needs.
Aug 3, 2026, 09:44 UTC
Kelun Pharma announced that as of July 31, 2026, it had repurchased 350,000 shares through centralized bidding, representing 0.02% of total shares, with a transaction amount of 10.366 million yuan (excluding transaction fees) and a repurchase price range of 29.55 to 29.702 yuan per share.
Source:
- finance.sina.cn
Aug 2, 2026, 08:14 UTC
Kelun Pharma and its subsidiaries participated in the 12th national centralized drug procurement on July 31, 2026, with 14 products preliminarily winning the bid, including sacubitril/valsartan sodium tablets.
Source:
- finance.sina.cn
Jul 27, 2026, 11:07 UTC
Kelong Pharmaceutical's subsidiary Kelun-Biotech's SKB565 new drug clinical trial application was approved by China's National Medical Products Administration for the treatment of advanced solid tumors.
Source:
- finance.sina.cn
- aastocks.com

002422.SZ

China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

Kelun Pharmaceutical announced a cash dividend of 1.26 yuan (pre-tax) per 10 shares.

Kelun Pharmaceutical released its 2026 interim report, reporting revenue of 8.839 billion yuan (down 2.7% year-on-year) and net profit attributable to shareholders of 1.128 billion yuan (up 12.71% year-on-year).

Kelun Pharmaceutical's controlling shareholder Liu Gexin released a pledge of 9.167 million shares and pledged 6.9 million shares for personal funding needs.

Kelun Pharma announced that as of July 31, 2026, it had repurchased 350,000 shares through centralized bidding, representing 0.02% of total shares, with a transaction amount of 10.366 million yuan (excluding transaction fees) and a repurchase price range of 29.55 to 29.702 yuan per share.

Kelun Pharma and its subsidiaries participated in the 12th national centralized drug procurement on July 31, 2026, with 14 products preliminarily winning the bid, including sacubitril/valsartan sodium tablets.

Kelong Pharmaceutical's subsidiary Kelun-Biotech's SKB565 new drug clinical trial application was approved by China's National Medical Products Administration for the treatment of advanced solid tumors.